학술논문
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Document Type
Article
Author
Temesgen, Zelalem; Burger, Charles D; Baker, Jason; Polk, Christopher; Libertin, Claudia R; Kelley, Colleen F; Marconi, Vincent C; Orenstein, Robert; Catterson, Victoria M; Aronstein, William S; Durrant, Cameron; Chappell, Dale; Ahmed, Omar; Chappell, Gabrielle; Badley, Andrew D; Lewis, Meghan; Sher, Linda; Bowdish, Michael; Wald-Dickler, Noah; Biswas, Subarna; Lam, Lydia; Vo, Khang; Poblete, Roy; Lee, May M.; Hutcheon, Douglass; Patron, Roberto; Gharbin, John; Moran, Caitlin; Kandiah, Sheetal; Cantos, Valeria; Rebolledo, Paulina; del Rio, Carlos; Lennox, Jeffrey; Polito, Carmen; Sheth, Anandi; Patel, Anup; Paniagua, Homero; Yohannes, Seife; Amin, Alpesh; Lee, Richard; Watanabe, Miki; Hsieh, Lanny; Cearras, Martin; Parikh, Amay; Sniffen, Jason; Onyia, Wilfred; Boger, Michael; Davidson, Lisa; Gajurel, Kiran; Leonard, Michael; McCurdy, Lewis; Quezada, Nestor; Sampson, Mindy; Shahid, Zainab; Strollo, Stephanie; Weinrib, David; Zulfigar, Sara; McDonald, Cheryl; Hollingsworth, John; Burk, John; Berg, Joshua; Barbaro, Daniel; Miller, Andrew; Sambathkumar, Lakshmi; McDonald, Stuart; Okoye, Obinna; Pulido, Juan; Fulton, Jennifer; Gill, William; Zuckerman, Richard; Lewis, Lionel; Mandapakala, Chaitanya; Robinson, Matthew; Metzger, Brian; Alam, Maqsood; Politis, Chrisoula; Frosch, Anne; Ngo, Linh; Carvalho Neuenschwander, Fernando; Figueiredo, EstevÃo; CanÇado, Gualter; Araujo, Gustavo; GuimarÃes, Lucas; Diaz, Ricardo; Bacellar, Natalia; Silva, Celso; Ferreira, Paulo; Andrade Lima, Marina; Uber Ghisi, Caroline; Anton, Camila; Albaneze, Ricardo; Wagner de Castro Lima Santos, Daniel; Iglessias, Ana Caroline; Lago, Marianna; Pietrobom, Paula; Alves, Maysa; Duailibe Furtado, Juvencio José; Trevelin, Leopoldo; Telles, Valeria; Correa, Francini; Ramos, Fabiano; de A. R. Da Silva, Marina; Lacerda Garcia, Rebeca C.; Maldonado, Ana Elizabeth G.; Beheregaray, Ana Carolina M.; Ortiz, Ana Maria T.; Luz, Kleber; Pipolo Milan, Eveline; Soares de Castro, Janine; Barbosa Moreira, Matheus José; Bezerra Onofre, Renata; do Nascimento JÁcome, TÁcito; Barreto Garcia, Victor; Rolim de Souzafrom, Victor Matheus; Dal Pizzol, Felipe; Ritter, Cristiane; Vinhas, Marcelo B.; Westheimer Cavalcante, Adilson Joaquim; Minghini, Julia; Dorigo, Loni; Salgado Miranda, Marina; Antila, Martti Anton; Brugnolli, Rebeca; Antila, Henrikki
Source
The Lancet Respiratory Medicine; 20210101, Issue: Preprints
Subject
Language
ISSN
22132600; 22132619
Abstract
The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments.